Adriano Chio

Professor of Neurology

University of Turin

Italy

Research Interests

Explore related searches

Professors in Italy

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Adriano Chio is a Professor of Neurology at the University of Turin, Italy. His research primarily focuses on amyotrophic lateral sclerosis (ALS), examining therapeutic goals, quality of life assessments, respiratory function, and nutritional implications. He has contributed to several significant studies and guidelines related to ALS management and treatment efficacy. His recent publications highlight his commitment to advancing the understanding and care of patients with neuromuscular diseases.

Articles (17)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (18)

Francesca Luisa Conforti

Associate Professor in Medical Genetics

University of Calabria

ITALY

Adriano Chio

Research Interests

Explore related searches

Contact this professor

About

Articles (17)

Minimum clinically important difference for drug effectiveness in an area of patient-oriented therapeutic goals in amyotrophic lateral sclerosis

Respiratory measurements, respiratory symptoms, and quality of life in ALS: results from the REVEALS study

REVEALS—a longitudinal cohort study of multifaceted respiratory assessment in ALS

Calculated Maximal Volume Ventilation (cMVV) as a Marker of Early Respiratory Failure in Amyotrophic Lateral Sclerosis (ALS)

Serum heat shock protein concentrations are not associated with amyotrophic lateral sclerosis risk or survival in three European populations

European Academy of Neurology (EAN) guideline on the management of amyotrophic lateral sclerosis in collaboration with European Reference Network for Neuromuscular Diseases (ERNEURO‐NMD)

Feasibility assessment of using the MiToS staging system for conducting economic evaluation in amyotrophic lateral sclerosis

Health utilities and quality-adjusted life years for patients with amyotrophic lateral sclerosis receiving reldesemtiv or placebo in FORTITUDE-ALS

Mycotoxins and Amyotrophic Lateral Sclerosis: food exposure, nutritional implications and dietary solutions

Crushing riluzole tablets: evaluation of loss of powder and active principle in a home-simulation experiment

COURAGE-ALS: a randomized, double-blind phase 3 study designed to improve participant experience and increase the probability of success

Impact of occupational categories on the incidence of amyotrophic lateral sclerosis in Sardinia Island, Italy

MiToS and King’s staging as clinical outcome measures in ALS: a retrospective analysis of the FORTITUDE-ALS trial

The future of ALS diagnosis and staging: where do we go from here?

Plasma CHI3L1 in Amyotrophic Lateral Sclerosis: A Potential Differential Diagnostic Biomarker

The “metabolic axis” of ALS: The role of body weight in disease pathogenesis

The <i>HFE</i> p.H63D (p.His63Asp) Polymorphism Is a Modifier of ALS Outcome in Italian and French Patients with <i>SOD1</i> Mutations

Collaborators (18)

Francesca Luisa Conforti

Christopher McDermott

Nilo Riva

Andrea CALVO

Cristina Moglia

philippe corcia

Paolo Volanti

Caroline Ingre

Umberto Manera

Ammar Al-Chalabi

Daniela Marchis

Paola Mandich

Stefano Callegaro

Marcella Zollino

Deirdre Murray

Jeremy M. Shefner

Antonella Casiraghi

Alessandro Bombaci

Make your next move.